4.22 times higher risk of bowel obstruction, whereby food is prevented from passing through the small or large intestine, resulting in symptoms like cramping, bloating, nausea and vomiting
Efficacy and safety of tirzepatide once weekly versus placebo for maintenance of weight loss in participants without type 2 diabetes who have obesity or are overweight with weight-related comorbidities: a randomized, double-blind, placebo-controlled trial (SURMOUNT-4)
Due to findings of thyroid C-cell tumours in rodent studies, patients with a personal or family history of medullary thyroid carcinoma (MTC) or those with multiple endocrine neoplasia syndrome type 2 (MEN 2) should be carefully evaluated regarding the benefit-risk balance of using semaglutide
Vaz F.M., Wanders R.J.A
Source: Gordie Center for Substance Abuse Prevention at the University of Virginia Inspiring positive change starts with education.
Your dose may need to go up to match your individual tolerance and weight loss goals, but your monthly price stays flatPlexusDx's commitment to transparent, non-punitive dosing
